v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2024   24,217,508      
Beginning balance at Dec. 31, 2024 $ 354,566 $ 6 $ 600,897 $ (235,564) $ (10,773)
Increase (Decrease) in Stockholders' Equity          
Net loss (10,659)     (10,659)  
Other comprehensive loss (853)       (853)
Restricted stock (in shares)   601,547      
Restricted stock 3,859   3,859    
Issuance of common stock (in shares)   8,922      
Issuance of common stock 233   233    
Ending balance (in shares) at Mar. 31, 2025   24,827,977      
Ending balance at Mar. 31, 2025 347,146 $ 6 604,989 (246,223) (11,626)
Beginning balance (in shares) at Dec. 31, 2024   24,217,508      
Beginning balance at Dec. 31, 2024 354,566 $ 6 600,897 (235,564) (10,773)
Increase (Decrease) in Stockholders' Equity          
Net loss (17,772)        
Other comprehensive loss 5,827        
Capital contribution associated with reclassification of MedTech liability to equity 2,062        
Ending balance (in shares) at Jun. 30, 2025   25,072,502      
Ending balance at Jun. 30, 2025 355,514 $ 6 613,790 (253,336) (4,946)
Beginning balance (in shares) at Mar. 31, 2025   24,827,977      
Beginning balance at Mar. 31, 2025 347,146 $ 6 604,989 (246,223) (11,626)
Increase (Decrease) in Stockholders' Equity          
Net loss (7,113)     (7,113)  
Other comprehensive loss 6,680       6,680
Restricted stock (in shares)   178,552      
Restricted stock 5,252   5,252    
Issuance of common stock (in shares)   55,143      
Issuance of common stock 1,261   1,261    
Stock portion of MedTech anniversary payment (in shares)   10,830      
Stock portion of MedTech anniversary payment 226   226    
Capital contribution associated with reclassification of MedTech liability to equity 2,062   2,062    
Ending balance (in shares) at Jun. 30, 2025   25,072,502      
Ending balance at Jun. 30, 2025 355,514 $ 6 613,790 (253,336) (4,946)
Beginning balance (in shares) at Dec. 31, 2025   25,093,792      
Beginning balance at Dec. 31, 2025 346,596 $ 6 622,325 (275,212) (523)
Increase (Decrease) in Stockholders' Equity          
Net loss (10,687)     (10,687)  
Other comprehensive loss (881)       (881)
Restricted stock (in shares)   496,378      
Restricted stock 3,427   3,427    
Issuance of common stock (in shares)   14,730      
Issuance of common stock 257   257    
Ending balance (in shares) at Mar. 31, 2026   25,604,900      
Ending balance at Mar. 31, 2026 338,712 $ 6 626,009 (285,899) (1,404)
Beginning balance (in shares) at Dec. 31, 2025   25,093,792      
Beginning balance at Dec. 31, 2025 346,596 $ 6 622,325 (275,212) (523)
Increase (Decrease) in Stockholders' Equity          
Net loss (17,850)        
Other comprehensive loss 3,755        
Capital contribution associated with reclassification of MedTech liability to equity 0        
Ending balance (in shares) at Jun. 30, 2026   26,111,426      
Ending balance at Jun. 30, 2026 343,614 $ 7 633,437 (293,062) 3,232
Beginning balance (in shares) at Mar. 31, 2026   25,604,900      
Beginning balance at Mar. 31, 2026 338,712 $ 6 626,009 (285,899) (1,404)
Increase (Decrease) in Stockholders' Equity          
Net loss (7,163)     (7,163)  
Other comprehensive loss 4,636       4,636
Restricted stock (in shares)   272,223      
Restricted stock 3,632 $ 1 3,631    
Issuance of common stock (in shares)   80,873      
Issuance of common stock 1,399   1,399    
Stock portion of MedTech anniversary payment (in shares)   153,430      
Stock portion of MedTech anniversary payment 2,398   2,398    
Ending balance (in shares) at Jun. 30, 2026   26,111,426      
Ending balance at Jun. 30, 2026 $ 343,614 $ 7 $ 633,437 $ (293,062) $ 3,232